Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders

a technology of fibromyalgia and other disorders, which is applied in the direction of immunological disorders, drug compositions, peptide/protein ingredients, etc., can solve the problems of disappointing clinical trials and modest success of treating fibromyalgia with a single pharmacological agent, and achieve the effects of decreasing slow wave sleep, increasing slow wave sleep, and increasing slow wave sleep

Inactive Publication Date: 2009-08-13
PFIZER INC
View PDF21 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides ways to increase slow waves sleep by giving certain substances like morphine or other opiate drugs to humans who are experiencing reduced sleepiness. These techniques can help people fall back into their deeper stages of restorative sleep without having to stop working again.

Problems solved by technology

This patent describes a problem with identifying specific causes of peripheral nerve disease called Focal Cord Tackie Stress Syndrome (FSC), which affects up to 50% of people worldwide who suffer from them. While there may be many ways to manage it, such as physical exercise, relaxation techniques, cognitive behavior modification strategies, and drug therapy, none provide effective solutions due to its multifactorial nature.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders
  • Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders
  • Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders

Examples

Experimental program
Comparison scheme
Effect test

example 2

Synthesis of Example 2

(3R,4S)-3-Aminomethyl-4,5-dimethyl-hexanoic acid

[0271]

Reagents and Conditions

[0272]a) (R)-(−)-4-phenyl-2-oxazolidinone, (CH3)3CCOCl, Et3N, LiCl, THF, −20 to 23° C.;[0273]b) MeMgCl, CuBrSMe2, THF, −35° C.;[0274]c) NaHMDS, BrCH2CO2tBu, THF, −78° C. to −40° C.;[0275]d) LiOH, H2O2, THF, H2O, 25° C.;[0276]e) BH3SMe2, THF, 0 to 25° C.;[0277]f) pTsCl, pyridine, 25° C.;[0278]g) NaN3, DMSO, 60° C.;[0279]h) Raney nickel, MeOH, H2; i) 3M HCl, reflux, ion exchange resin (Dowex 50WX8, strongly acidic).

[R-(E)]3-(4-Methyl-pent-2-enoyl)-4-phenyl-oxazolidin-2-one 16

[0280]Trimethylacetyl chloride (7.8 g, 0.065 mol) was added to acid 14 (6.9 g, 0.06 mol) and triethylamine (18 g, 0.187 mol) in THF (200 mL) at −20° C. After 1 hour, lithium chloride (2.35 g, 0.55 mol) and (R)-(−)-4-phenyl-2-oxazolidinone (8.15 g, 0.05 mol) were added and the thick suspension warmed to room temperature. After 20 hours, the suspension was filtered and the filtrate concentrated. The resultant solid was re

specific examples

Example 3

Synthesis of 3-Aminomethyl-5-methyl-octanoic acid

[0635]

1-Benzyl-4-hydroxymethyl-pyrrolidine-2-one 74

[0636]Sodium borohydride (8.0 g, 0.211 mol) was added to a solution of methyl-1-benzyl-5-oxo-3-pyrrolidnecarboxylate 73 (See Zoretic et al, J. Org. Chem., 1980; 45:810-814 for general method of synthesis) (32.0 g, 0.137 mol) in 1,2-dimethoxyethane (600 mL) and refluxed for 19 hours. The reaction was cooled to room temperature and 200 mL of water was added. The reaction was quenched with 1 M citric acid and concentrated under reduced pressure. The residue was extracted with dichloromethane, dried over magnesium sulfate, and evaporated to dryness to give 17.47 g, 62% of the alcohol 74 as clear oil. 1H NMR (CDCl3) δ 7.30 (m, 5M), 4.38 (d, 1H, J=14.7), 4.46 (d, 1H, J=14.7), 3.56 (m, 2H), 3.36 (m, 1H), 3.10 (m, 1H), 2.52 (m, 2H), 2.26 (m, 1H). MS, m / z (relative intensity): 207 [M+2H, 66%]. IR (KBr) 3345, 2946, 2866, 1651, 1445, 1025, 737, and 698 cm−1.

1-Benzyl-4-iodomethyl-pyrrolid

example 4

Synthesis of 3-Aminomethyl-5,7-dimethyl-octanoic acid

[0641]

1-(4-Methoxy-benzyl)-5-oxo-pyrrolidine-3-carboxylic acid methyl ester 79

[0642]To 4-methoxybenzylamine (42 g, 0.306 mol) in methanol (40 mL) at 0° C. was added the dimethyl itaconate (48 g, 0.306 mol) in methanol (13 mL). The solution was stirred at room temperature for 4 days. 1N HCl was added to the solution followed by ether. The two layers were separated and the aqueous phase extracted with ether. The combined organic phases were dried (MgSO4). Upon filtration of the drying agent the desired material 79 precipitated from solution that was collected and dried under vacuum. 23.26 g, 29%. MS, m / z (relative intensity): 264 [M+H, 100%]. Anal. Calcd for C14H17N1O4: C, 63.87; H, 6.51; N, 5.32. Found: C, 63.96; H, 6.55; N, 5.29.

4-Hydroxymethyl-1-(4-methoxy-benzyl)-pyrrolidine-2-one 80

[0643]NaBH4 (15 g, 0.081 mol) was added in portions to ester 79 in ethanol (600 mL) at room temperature. After 4.5 hours water (˜200 mL) was carefull

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Electrical conductanceaaaaaaaaaa
Login to view more

Abstract

This invention relates to a method of treating certain disorders by administering a compound of the formula 1
or a pharmaceutically acceptable salt thereof, wherein:
    • R1 is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; and
    • R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S,5R)-3-aminomethyl-5-methyl-octanoic acid.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner PFIZER INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products